{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:18:30Z","timestamp":1790983110981,"version":"4.1.0"},"reference-count":35,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Drug Safety"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Oxaliplatin commonly induces acute, transient peripheral neurotoxicity, most often presenting as cold-induced paresthesia. Ocular adverse events are rare and poorly understood. This case describes a rare, reproducible transient monocular visual field loss associated with oxaliplatin exposure. We report a patient treated with FOLFOX (5-FU\u2009+\u2009oxaliplatin) for metastatic rectal cancer who developed recurrent transient visual symptoms temporally associated with oxaliplatin infusion. Biological, neurological, and ophthalmological evaluations were performed. The patient experienced recurrent, transient left monocular vertical hemifield loss during oxaliplatin administration. Extensive neurological and ophthalmological investigations were unremarkable. Symptoms were fully reversible and reproducible across treatment cycles, occurring exclusively after oxaliplatin exposure. This case adds to the limited literature on oxaliplatin-associated ocular neurotoxicity and emphasizes that transient visual symptoms may represent a reversible form of acute neurotoxicity. Recognizing this entity is important to avoid premature discontinuation of an effective chemotherapy regimen.<\/jats:p>","DOI":"10.1177\/20420986261467894","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:07:10Z","timestamp":1788264430000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Transient monocular vertical hemifield loss as a rare acute oxaliplatin-induced ophthalmological side effect: a case report and review of the literature"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0400-8127","authenticated-orcid":false,"given":"Lucie","family":"Regaldo-Saint Blancard","sequence":"first","affiliation":[{"name":"Medical Oncology, Bergoni\u00e9 Institute, Bordeaux, Nouvelle-Aquitaine 33000, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Pernot","sequence":"additional","affiliation":[{"name":"Medical Oncology, Bergoni\u00e9 Institute, Bordeaux, Nouvelle-Aquitaine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Fonck","sequence":"additional","affiliation":[{"name":"Medical Oncology, Bergoni\u00e9 Institute, Bordeaux, Nouvelle-Aquitaine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lola Jade","family":"Palmieri","sequence":"additional","affiliation":[{"name":"Medical Oncology, Bergoni\u00e9 Institute, Bordeaux, Nouvelle-Aquitaine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.4238"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70447-9"},{"key":"e_1_3_4_4_2","first-page":"249","article-title":"Management of oxaliplatin-induced peripheral neuropathy","volume":"1","author":"Saif MW","year":"2005","unstructured":"Saif MW, Reardon J. Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manage 2005; 1: 249\u2013258.","journal-title":"Ther Clin Risk Manage"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(03)00399-3"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10559"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.8533"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.056"},{"key":"e_1_3_4_9_2","article-title":"Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB\/Alliance)","author":"Loprinzi CL","unstructured":"Loprinzi CL, Qin R, Dakhil SR, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB\/Alliance). J Clin Oncol. PMID: 24297951.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_10_2","article-title":"Clinical management of oxaliplatin-associated neurotoxicity","volume":"5","author":"Grothey A.","year":"2005","unstructured":"Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 2005; 5: S38\u2013S46.","journal-title":"Clin Colorectal Cancer"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-0134(99)00135-X"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199513040-00003"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1188\/06.CJON.227-229"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2007.07.162"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155209104383"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000322675"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155211401455"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3109\/15569527.2014.944647"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/030089161309900516"},{"key":"e_1_3_4_20_2","article-title":"Reversible ocular toxicity of oxaliplatin: a case report","volume":"11","author":"Noor A","year":"2019","unstructured":"Noor A, Desai A, Singh M. Reversible ocular toxicity of oxaliplatin: a case report. Cureus 2019; 11: e4582.","journal-title":"Cureus"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211004985"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000514656"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000516271"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfo.2020.10.013"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1159\/000521842"},{"issue":"2","key":"e_1_3_4_26_2","first-page":"1094","article-title":"Monocular tunnel vision produced by oxaliplatin","volume":"3","author":"Schiappacasse GV.","year":"2023","unstructured":"Schiappacasse GV. Monocular tunnel vision produced by oxaliplatin. J Oncol 2023; 3(2): 1094.","journal-title":"J Oncol"},{"key":"e_1_3_4_27_2","article-title":"Oxaliplatin induced crystalline retinopathy","volume":"33","author":"Shahi F","year":"2023","unstructured":"Shahi F, Makateb A, Khojasteh H, et al. Oxaliplatin induced crystalline retinopathy. Int J Clin Stud Med Case Rep 2023; 33.","journal-title":"Int J Clin Stud Med Case Rep"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.949346"},{"issue":"37","key":"e_1_3_4_29_2","first-page":"603","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development","volume":"110","author":"Gagnier JJ","year":"2013","unstructured":"Gagnier JJ, Kienle G, Altman DG, et al. The CARE guidelines: consensus-based clinical case reporting guideline development. Dtsch Arztebl Int 2013; 110(37): 603\u2013608.","journal-title":"Dtsch Arztebl Int"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101265"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)74224-2"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(95)30866-4"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2010.183244"},{"key":"e_1_3_4_34_2","article-title":"Bilateral sequential Non-arteritic Anterior Ischaemic Optic Neuropathy (NA-AION) presumed secondary to 5-fluorouracil (5-FU): a case report and literature review","volume":"16","author":"Agarwal P","year":"2024","unstructured":"Agarwal P, Khera M. Bilateral sequential Non-arteritic Anterior Ischaemic Optic Neuropathy (NA-AION) presumed secondary to 5-fluorouracil (5-FU): a case report and literature review. Cureus 2024; 16: e72754.","journal-title":"Cureus"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2024.09.019"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2005.11.001"}],"container-title":["Therapeutic Advances in Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420986261467894","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20420986261467894","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420986261467894","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:48:51Z","timestamp":1788518931000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20420986261467894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"alternative-id":["10.1177\/20420986261467894"],"URL":"https:\/\/doi.org\/10.1177\/20420986261467894","relation":{},"ISSN":["2042-0986","2042-0994"],"issn-type":[{"value":"2042-0986","type":"print"},{"value":"2042-0994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"article-number":"20420986261467894"}}